Brain Disease Market Growth, Trends, and Analysis by 2031

Coverage: Brain Disease Market covers analysis By Disease Type (Brain Cancer, Alzheimer Disease, Alcoholism, Amnesia Epilepsy, Meningitis, Others); Distribution Channel (Hospitals Pharmacy, Online Pharmacy), and Geography (North America, Europe, Asia Pacific, and South and Central America)

  • Report Code : TIPRE00017791
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

The Brain Disease Market is expected to register a CAGR of 7.10% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.

The report is segmented by Disease Type (Brain Cancer, Alzheimer's Disease, Alcoholism, Amnesia Epilepsy, Meningitis, and Others); and Distribution Channel (hospital pharmacy, Online Pharmacy). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.

Purpose of the Report

The report Brain Disease Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  • Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  • Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  • Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Brain Disease Market Segmentation

Disease Type
  • Brain Cancer
  • Alzheimer Disease
  • Alcoholism
  • Amnesia Epilepsy
  • Meningitis
Distribution Channel
  • Hospitals Pharmacy
  • Online Pharmacy

Strategic Insights

Brain Disease Market Growth Drivers
  • Rising Incidence of Neurodegenerative Diseases: One of the major growth drivers in the brain disease market is the increasing incidence of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. The aging global population results in more cases of age-related neurological disorders which increases the need for brain disease treatments. Neurodegenerative diseases show progressive nerve cell degeneration in the brain which causes cognitive decline together with motor dysfunction and various other debilitating effects. Alzheimer’s disease ranks as one of dementia’s most widespread forms which impacts millions across the globe. The expanding elderly population which ages serves as the main risk factor for these conditions and leads to their increased prevalence. The rising global average age demands more efficient diagnostics and treatment options for neurodegenerative diseases along with improved supportive care for affected individuals. The market for brain disease treatments is expanding as the demand for novel therapies and early diagnostic tools grows. The detection of neurodegenerative diseases in earlier stages improves symptom management and patient outcomes because of growing awareness about these conditions and healthcare system improvements along with advanced neuroimaging technology. Pharmaceutical companies are working to develop new drugs which target the root causes of neurodegenerative diseases like the amyloid plaque accumulation in Alzheimer’s disease and the dopamine depletion seen in Parkinson’s disease. The quest for advanced treatments generates more investment in brain disease research and makes neurodegenerative disorders the main concern for scientists and medical professionals.
  • Advances in Neurostimulation and Brain Modulation Technologies: Neurostimulation advancements along with brain modulation technologies have brought transformative solutions to treating multiple brain diseases which include depression, chronic pain and neurological disorders. Non-invasive and minimally invasive brain-targeting therapies such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) are becoming more prevalent. Non-responsive patients to standard pharmaceutical therapies find these techniques especially useful. Deep brain stimulation has demonstrated positive outcomes for Parkinson’s disease and essential tremors treatment and has even shown efficacy in depression management which results in improved patient quality of life. Healthcare practitioners are using TMS more frequently for individuals who have depression that does not respond to standard drug treatments. Clinical practice now demands neurostimulation devices more because evidence increasingly demonstrates their effectiveness. The latest progress in brain-computer interfaces (BCIs) creates new treatment potentials for paralysis and neurological disorders by enabling patients with serious motor limitations to communicate and move. Healthcare providers along with patients view these innovative technologies as appealing because they now deliver improved precision while producing fewer side effects. The brain disease market segment focused on brain modulation therapies is poised for growth because more applications are being developed while the demand for non-invasive treatments rises.
  • Expanding Knowledge of Brain Health and Disease Mechanisms: Research advancements in brain health and disease mechanisms create market growth opportunities through new drug discovery and therapy development pathways. Modern neuroscience breakthroughs in neurobiology and genetics enable scientists to gain improved insights into cellular and molecular brain disease processes. Targeted therapies for Alzheimer’s disease and Parkinson’s disease as well as multiple sclerosis emerged from discoveries about specific genes and biomarkers that drive these conditions. The study of neuroinflammation, protein aggregation and synaptic dysfunction reveals new therapeutic targets which helps pharmaceutical companies create better treatments. Scientists actively research innovative treatments including gene therapy and RNA-based therapies along with monoclonal antibodies to fight different brain diseases. Gene-editing tools like CRISPR show promise for fixing genetic mutations that cause some neurodegenerative diseases and provide hope for permanent solutions. Through the use of neuroimaging techniques like functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) researchers can now monitor brain activity while simultaneously observing disease progression as it happens. Breakthrough innovations are speeding up drug discovery which enables researchers to develop treatments that focus on specific genetic mutations and biomarkers more quickly. The brain disease market stands to experience substantial expansion as brain research achieves new discoveries while our understanding of brain diseases advances because personalized treatment demands are increasing.
Brain Disease Market Future Trends
  • Increasing Use of Digital Therapeutics for Brain Disease Management: The rise of digital therapeutics is a transformative trend in the brain disease market. Digital therapeutics encompasses evidence-based treatment methods that are provided to patients through digital platforms including mobile apps along with video games and virtual reality systems. The interventions aim to either treat or prevent brain diseases including depression as well as ADHD and anxiety. Patients now prefer digital therapeutics because they offer customized treatment options which are both affordable and easily obtainable. VR therapy is becoming more common for managing conditions such as post-traumatic stress disorder (PTSD), depression and cognitive rehabilitation. Patients with depression and anxiety experience improved stress management and modified negative thought patterns through cognitive behavioral therapy delivered by digital tools. The COVID-19 pandemic accelerated telemedicine acceptance which expanded digital therapeutic adoption helping patients access healthcare services from their homes. Artificial intelligence (AI) integration into therapeutic platforms enables real-time patient progress tracking and treatment plan modifications. Digital therapeutics are becoming part of standard healthcare systems due to their personalized approach and growing evidence proving their effectiveness. The digital therapeutics market for brain diseases will expand quickly as healthcare providers and patients adopt these innovations which presents technology companies with chances to develop fresh products and increase their market share.
  • Increased Focus on Early Detection and Precision Medicine in Brain Disease: The brain disease market now prominently focuses on early detection and precision medicine as its key trends. Neurodegenerative disorders including Alzheimer’s and Parkinson’s disease usually go undetected until they become severe. Timely medical intervention proves essential to better patient results and to decelerate disease advancement. Healthcare researchers and providers are allocating more resources to develop tools and technologies for identifying brain diseases at an early stage. Functional MRI and positron emission tomography (PET) advancements enable doctors to detect structural and functional brain alterations during the pre-symptomatic phase of neurodegenerative diseases. The discovery of biomarkers for early detection of diseases such as Alzheimer’s and Huntington’s is progressing which results in the creation of blood tests and new diagnostic tools. The approach of precision medicine which customizes treatments according to each patient's genetic profile, lifestyle choices, and specific disease traits is receiving increased acceptance. Scientists study the integration of genetic information and environmental factors with individual-specific characteristics in treatment plans to develop more tailored and effective medical therapies. Market expansion for brain disease treatments is anticipated as needs for early diagnosis and precision medicine increase. This trend becomes particularly important because brain disease rates rise alongside an aging worldwide population which demands more proactive and personalized healthcare strategies. Precision medicine can deliver treatments that better target illnesses while reducing side effects which makes it a powerful driver for innovation and market growth in brain disease treatments.
  • Personalized Medicine and Biomarker Discovery for Brain Diseases: Personalized medicine is gradually becoming an inevitable approach to treatment for brain diseases because medical experts realize that different patients have different needs which cannot be treated with universal approaches. In personalized medicine, treatments are tailored on every patient's specific genetic makeup along with their personal life choices and their disease biomarkers. The genomics and biomarker discovery advancements help the brain disease market as they enable researchers to create targeted therapies for Alzheimer's disease, Parkinson's disease, and schizophrenia. Early diagnosis of brain diseases relies on biomarkers to assess disease severity and track treatment success. Researchers who have identified genetic markers linked to Alzheimer's disease can now create drugs that target these markers to potentially stop or slow down disease advancement. Personalized treatment methods for brain diseases are improving predictions of patient responses to particular therapies which leads to more efficient and successful management of these conditions. Modern diagnostic techniques like genetic testing and liquid biopsies coupled with neuroimaging are raising greater prospects for the discovery of new biomarkers and personalization of treatment of brain diseases. The pattern improves patient outcomes while speeding up novel drug development to tackle causes of brain diseases which, in turn, helps pharmaceutical companies operating in the brain disease category.
Brain Disease Market Opportunities
  • Growing Demand for Brain Disease Prevention and Wellness Programs: The market for brain disease prevention has found new growth potential because of increased focus on preventive care and wellness programs. The worldwide increase in brain health awareness leads to more individuals actively looking for methods to lower their chances of getting brain diseases like dementia and Alzheimer's along with other neurodegenerative disorders. The popularity of programs that support brain health through methods like cognitive training and physical exercise as well as healthy eating is increasing as preventive measures. Research shows that lifestyle changes like physical activity along with cognitive exercises and a balanced diet help decrease the risk of cognitive decline. Consumers who want to track and improve their brain health now have easy access to brain wellness applications and digital platforms that provide cognitive testing and brain training exercises. As preventive care programs become more widely accepted companies that offer cognitive health products and services find significant growth opportunities. The combination of public health campaigns about brain diseases and the increased attention to early detection and prevention will create a market demand for new products that enhance brain wellness. The transition to brain health as a part of general well-being creates major growth possibilities for businesses selling products and services that work to stop brain diseases.
  • Collaborative Partnerships and Research Advancements in Brain Disease Treatments: The brain disease market presents growth potential through collaborative partnerships and research advancements which focus on creating new treatments for brain conditions. Due to the intricate nature of brain diseases and the major obstacles in drug development pharmaceutical companies have teamed up with academic institutions, biotechnology firms and healthcare providers. Through these partnerships organizations combine their resources and expertise to meet the medical requirements that current treatments for brain diseases have not yet fulfilled. Through joint research activities in neurobiology, genomics and neuroinflammation scientists are learning more about what causes brain diseases which leads to the creation of innovative treatment options. Research community attention has centered on targeted Alzheimer's treatments based on amyloid plaques and tau tangles research insights. The joint research efforts in stem cell therapies along with gene editing technologies and immunotherapies stand to transform how neurodegenerative diseases are treated. Research organizations and universities work together with biotech firms and pharmaceutical companies to expedite the development of innovative treatments. Through international research networks and consortia medical research gains access to expanded clinical trials and expedited drug development along with better patient recruitment systems. Scientific advancements along with technological growth will ensure that partnerships remain essential for creating successful brain disease treatments. Stakeholders in the brain disease market can leverage collaborative research initiatives to create innovative solutions and exploit new treatment pathways.
  • Development of Combination Therapies for Complex Brain Diseases: The recognition that brain diseases result from multiple factors creates opportunities to develop combination therapies. Combination therapies use several drugs or treatment methods at once to attack multiple aspects of a disease which improves overall treatment success. Because brain diseases like Alzheimer’s, Parkinson’s, and depression have intricate underlying mechanisms multiple therapeutic paths need to be targeted together instead of just one. Scientists study how existing medications combined with new therapeutic approaches can lead to better patient results. Combination therapies can use neuroprotective agents along with anti-inflammatory or immunomodulatory treatments to reduce neurodegenerative disease progression. Positive results from combination therapies in cancer and HIV research have led scientists to explore similar methods for treating brain diseases. Pharmaceutical companies fund research into combination drug regimens because they could deliver superior treatment options for patients with complicated brain disorders. The rising demand for combination therapies creates substantial market opportunities through new drug development and enhanced therapeutic outcomes.

Market Report Scope

Key Selling Points

  • Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Brain Disease Market, providing a holistic landscape.
  • Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  • Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  • Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Brain Disease Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.

REGIONAL FRAMEWORK
World Geography

Have a question?

Analyst

Mrinal

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst   Speak to Analyst
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
MARKET PLAYERS
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the expected CAGR of the Brain Disease Market?

The Brain Disease Market is estimated to witness a CAGR of 7.10% from 2025 to 2031.

What are the driving factors impacting the Brain Disease Market?

The major factors driving the Brain Disease Market are Rising Incidence of Neurodegenerative Diseases, Advances in Neurostimulation and Brain Modulation Technologies, and Expanding Knowledge of Brain Health and Disease Mechanisms.

What are the future trends of the Brain Disease Market?

Future trends in the Brain Disease Market are Increasing Use of Digital Therapeutics for Brain Disease Management, Increased Focus on Early Detection and Precision Medicine in Brain Disease, and Personalized Medicine and Biomarker Discovery for Brain Diseases.

Which are the leading players in the Brain Disease Market?

Some of the players operating in the market are Pfizer Inc., Eli Lilly, F. Hoffmann La Roche AG, GE Healthcare, Janssen Pharmaceuticals, Abbvie Inc., Allergan PLC,  Merck and Co, Novartis AG, AstraZeneca plc.

What are the deliverable formats of the Brain Disease Market report?

The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.

What are the options available for the customization of this report?

Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Brain Disease Market - By Disease Type
1.3.2 Brain Disease Market - By Distribution Channel
1.3.3 Brain Disease Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BRAIN DISEASE MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BRAIN DISEASE MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BRAIN DISEASE MARKET - GLOBAL MARKET ANALYSIS
6.1. BRAIN DISEASE - GLOBAL MARKET OVERVIEW
6.2. BRAIN DISEASE - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. BRAIN DISEASE MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. BRAIN CANCER
7.3.1. Overview
7.3.2. Brain Cancer Market Forecast and Analysis
7.4. ALZHEIMER DISEASE
7.4.1. Overview
7.4.2. Alzheimer Disease Market Forecast and Analysis
7.5. ALCOHOLISM
7.5.1. Overview
7.5.2. Alcoholism Market Forecast and Analysis
7.6. AMNESIA EPILEPSY
7.6.1. Overview
7.6.2. Amnesia Epilepsy Market Forecast and Analysis
7.7. MENINGITIS
7.7.1. Overview
7.7.2. Meningitis Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. BRAIN DISEASE MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS PHARMACY
8.3.1. Overview
8.3.2. Hospitals Pharmacy Market Forecast and Analysis
8.4. ONLINE PHARMACY
8.4.1. Overview
8.4.2. Online Pharmacy Market Forecast and Analysis
9. BRAIN DISEASE MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Brain Disease Market Overview
9.1.2 North America Brain Disease Market Forecasts and Analysis
9.1.3 North America Brain Disease Market Forecasts and Analysis - By Disease Type
9.1.4 North America Brain Disease Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Brain Disease Market Forecasts and Analysis - By Countries
9.1.5.1 United States Brain Disease Market
9.1.5.1.1 United States Brain Disease Market by Disease Type
9.1.5.1.2 United States Brain Disease Market by Distribution Channel
9.1.5.2 Canada Brain Disease Market
9.1.5.2.1 Canada Brain Disease Market by Disease Type
9.1.5.2.2 Canada Brain Disease Market by Distribution Channel
9.1.5.3 Mexico Brain Disease Market
9.1.5.3.1 Mexico Brain Disease Market by Disease Type
9.1.5.3.2 Mexico Brain Disease Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Brain Disease Market Overview
9.2.2 Europe Brain Disease Market Forecasts and Analysis
9.2.3 Europe Brain Disease Market Forecasts and Analysis - By Disease Type
9.2.4 Europe Brain Disease Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Brain Disease Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Brain Disease Market
9.2.5.1.1 Germany Brain Disease Market by Disease Type
9.2.5.1.2 Germany Brain Disease Market by Distribution Channel
9.2.5.2 France Brain Disease Market
9.2.5.2.1 France Brain Disease Market by Disease Type
9.2.5.2.2 France Brain Disease Market by Distribution Channel
9.2.5.3 Italy Brain Disease Market
9.2.5.3.1 Italy Brain Disease Market by Disease Type
9.2.5.3.2 Italy Brain Disease Market by Distribution Channel
9.2.5.4 Spain Brain Disease Market
9.2.5.4.1 Spain Brain Disease Market by Disease Type
9.2.5.4.2 Spain Brain Disease Market by Distribution Channel
9.2.5.5 United Kingdom Brain Disease Market
9.2.5.5.1 United Kingdom Brain Disease Market by Disease Type
9.2.5.5.2 United Kingdom Brain Disease Market by Distribution Channel
9.2.5.6 Rest of Europe Brain Disease Market
9.2.5.6.1 Rest of Europe Brain Disease Market by Disease Type
9.2.5.6.2 Rest of Europe Brain Disease Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Brain Disease Market Overview
9.3.2 Asia-Pacific Brain Disease Market Forecasts and Analysis
9.3.3 Asia-Pacific Brain Disease Market Forecasts and Analysis - By Disease Type
9.3.4 Asia-Pacific Brain Disease Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Brain Disease Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Brain Disease Market
9.3.5.1.1 Australia Brain Disease Market by Disease Type
9.3.5.1.2 Australia Brain Disease Market by Distribution Channel
9.3.5.2 China Brain Disease Market
9.3.5.2.1 China Brain Disease Market by Disease Type
9.3.5.2.2 China Brain Disease Market by Distribution Channel
9.3.5.3 India Brain Disease Market
9.3.5.3.1 India Brain Disease Market by Disease Type
9.3.5.3.2 India Brain Disease Market by Distribution Channel
9.3.5.4 Japan Brain Disease Market
9.3.5.4.1 Japan Brain Disease Market by Disease Type
9.3.5.4.2 Japan Brain Disease Market by Distribution Channel
9.3.5.5 South Korea Brain Disease Market
9.3.5.5.1 South Korea Brain Disease Market by Disease Type
9.3.5.5.2 South Korea Brain Disease Market by Distribution Channel
9.3.5.6 Rest of Asia-Pacific Brain Disease Market
9.3.5.6.1 Rest of Asia-Pacific Brain Disease Market by Disease Type
9.3.5.6.2 Rest of Asia-Pacific Brain Disease Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Brain Disease Market Overview
9.4.2 Middle East and Africa Brain Disease Market Forecasts and Analysis
9.4.3 Middle East and Africa Brain Disease Market Forecasts and Analysis - By Disease Type
9.4.4 Middle East and Africa Brain Disease Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Brain Disease Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Brain Disease Market
9.4.5.1.1 South Africa Brain Disease Market by Disease Type
9.4.5.1.2 South Africa Brain Disease Market by Distribution Channel
9.4.5.2 Saudi Arabia Brain Disease Market
9.4.5.2.1 Saudi Arabia Brain Disease Market by Disease Type
9.4.5.2.2 Saudi Arabia Brain Disease Market by Distribution Channel
9.4.5.3 U.A.E Brain Disease Market
9.4.5.3.1 U.A.E Brain Disease Market by Disease Type
9.4.5.3.2 U.A.E Brain Disease Market by Distribution Channel
9.4.5.4 Rest of Middle East and Africa Brain Disease Market
9.4.5.4.1 Rest of Middle East and Africa Brain Disease Market by Disease Type
9.4.5.4.2 Rest of Middle East and Africa Brain Disease Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Brain Disease Market Overview
9.5.2 South and Central America Brain Disease Market Forecasts and Analysis
9.5.3 South and Central America Brain Disease Market Forecasts and Analysis - By Disease Type
9.5.4 South and Central America Brain Disease Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Brain Disease Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Brain Disease Market
9.5.5.1.1 Brazil Brain Disease Market by Disease Type
9.5.5.1.2 Brazil Brain Disease Market by Distribution Channel
9.5.5.2 Argentina Brain Disease Market
9.5.5.2.1 Argentina Brain Disease Market by Disease Type
9.5.5.2.2 Argentina Brain Disease Market by Distribution Channel
9.5.5.3 Rest of South and Central America Brain Disease Market
9.5.5.3.1 Rest of South and Central America Brain Disease Market by Disease Type
9.5.5.3.2 Rest of South and Central America Brain Disease Market by Distribution Channel
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BRAIN DISEASE MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. BRAIN DISEASE MARKET, KEY COMPANY PROFILES
12.1. PFIZER INC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ELI LILLY
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. F. HOFFMANN LA ROCHE AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. GE HEALTHCARE
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. JANSSEN PHARMACEUTICALS
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ABBVIE INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ALLERGAN PLC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MERCK AND CO
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVARTIS AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. ASTRAZENECA PLC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Pfizer Inc.
2. Eli Lilly
3. F. Hoffmann La Roche AG
4. GE Healthcare
5. Janssen Pharmaceuticals
6. Abbvie Inc.
7. Allergan PLC
8. Merck and Co
9. Novartis AG
10. AstraZeneca plc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Life Sciences : READ MORE..